Clients

Tissue Regenix Group plc

Jan 29, 2021, 12:03 PM
Company EPIC Code : AIM: TRX
Company Name : Tissue Regenix Group plc
Company Sector : Pharmaceuticals & Biotechnology (Biotechnology)
Venue : online
Event Date : Sep 18, 2025, 15:00 PM

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.

Daniel Lee, Chief Executive Officer, and Jay LeCoque, Executive Chairman, will host a live online presentation relating to the interim results via the Investor Meet Company platform at 16:00 BST on Thursday 18 September. The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and register for the presentation here:  

https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor

16:00 BST on Thursday 18 September
 Event Date
Year End31 December
Half  Year End30 June
Preliminary Results*June
Interim Results18 September
AGM*June

* Months based on previous announcements of this kind

TRX PowerPoint Presentation
Load more comments
Thank you for the comment! Your comment must be approved first
avatar
New code

Who We Work With

Tissue Regenix Group plc

Jan 29, 2021, 12:03 PM
Company EPIC Code : AIM: TRX
Company Name : Tissue Regenix Group plc
Company Sector : Pharmaceuticals & Biotechnology (Biotechnology)
Venue : online
Event Date : Sep 18, 2025, 15:00 PM

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.

Daniel Lee, Chief Executive Officer, and Jay LeCoque, Executive Chairman, will host a live online presentation relating to the interim results via the Investor Meet Company platform at 16:00 BST on Thursday 18 September. The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and register for the presentation here:  

https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor

16:00 BST on Thursday 18 September
 Event Date
Year End31 December
Half  Year End30 June
Preliminary Results*June
Interim Results18 September
AGM*June

* Months based on previous announcements of this kind

TRX PowerPoint Presentation
Load more comments
Thank you for the comment! Your comment must be approved first
avatar
New code